Research library

B

grade

Ruxolitinib cream resulted in a 49% reduction in affected body surface area in patients with moderate atopic dermatitis, but results should be interpreted with caution due to the study's observational design.

49% reduction in affected body surface area with ruxolitinib cream.

summary

C

grade

This study shows widespread and intense pyrethroid resistance in mosquito populations in Oyo State, indicating a need for new vector control strategies beyond current methods.

Mortality for permethrin ranged from 5% (Egbeda) to 65% (Akinyele) at diagnostic dose.

summary

A

grade

The combination of TG4010 and nivolumab showed limited benefit in NSCLC, with only 1 of 12 evaluable patients responding and a median overall survival of 7.23 months.

Median overall survival was 7.23 months.

summary

B

grade

Patients who achieve successful dose reduction of abrocitinib may be characterized by shorter disease duration and lower atopic burden.

Not reported in abstract.

summary

C

grade

Helicteres ovata extract shows promise in reducing pain in murine models, but further research is needed to determine its effects in humans.

Not reported in abstract.

summary

C

grade

Processing Polygonum multiflorum, especially with black bean decoction, significantly reduces liver toxicity in a mouse model, but the implications for human health require further investigation.

PPM treatment reduced serum ALT by 82% compared to the PM group.

summary

B

grade

The feature-based Transformer achieved a high performance of 97.04% in distinguishing MCI from healthy controls, indicating potential for advanced EEG analysis in early detection.

97.04% ± 0.72 performance of the feature-based Transformer.

summary

B

grade

Early response to ivarmacitinib at week 4 is associated with better long-term efficacy in patients with moderate-to-severe atopic dermatitis.

EASI 75 response rates at week 16 were 81.9% in early responders vs. 47.2% in nonearly responders, p<0.001.

summary

C

grade

Supplementation with rumen-protected AD3E improved weight gain and feed efficiency in fattening lambs, but did not affect nutrient digestibility or intestinal morphology.

Final weight of lambs receiving protected vitamin supplement was higher than control group (P < 0.05).

summary

C

grade

The probe D4 shows promise for both imaging and cognitive improvement in a mouse model of Alzheimer's Disease, but further research is needed to confirm its efficacy in humans.

inhibition rate: 89.5%

summary

D

grade

Valproic acid's antidepressant-like effects in rodent models were first demonstrated in the late 1980s, which supports recent findings in the literature.

Not reported in abstract.

summary

B

grade

The prevalence of suicidal thoughts and behaviors is notably high in peri-urban Cape Town, with strong associations to mental health issues and social stressors.

14.0% prevalence of past 30-day suicidal ideation, n=613.

summary

C

grade

The study reveals that the D-peptide D-TLKIVWC can disassemble tau fibrils in vitro, but its clinical applicability is not established.

Not reported in abstract.

summary

C

grade

Microglial function in Alzheimer's disease may be influenced by the transcription factor PU.1 and the receptor CD28, suggesting new avenues for immunotherapy. However, findings from mouse models require cautious interpretation when considering human applications.

Not reported in abstract.

summary

B

grade

GLP-1 receptor agonists may help patients regain lost weight after bariatric surgery, but the evidence is based on a small cohort and requires cautious interpretation.

9.6% weight loss vs 4.3% in non-users at 6 months, p = 0.005.

summary

A

grade

iGlarLixi may offer better glycaemic control with lower insulin doses and hypoglycaemia risk in Chinese adults with Type 2 diabetes compared to IDegAsp.

HbA1c reductions were greater with iGlarLixi versus IDegAsp at Week 24.

summary

A

grade

Current evidence does not show a significant association between GLP-1 receptor agonist exposure and hypertensive disorders of pregnancy risk, but further research is needed.

OR 0.91, CI 0.57-1.47 for HDP risk with GLP-1 RA exposure.

summary

B

grade

SGLT2 inhibitors may be more kidney protective, while GLP-1 receptor agonists offer better cardiovascular protection, with effectiveness varying by kidney failure risk in veterans with type 2 diabetes.

SGLT2i users had a hazard ratio of 0.89 for kidney failure risk compared to GLP-1 RA users.

summary

D

grade

While some GLP-1 RAs show a significant association with suicidality, causality is not established, and clinical relevance is unclear.

Liraglutide ROR = 3.26, 95% CI = 2.53, 4.22 for suicidal ideation.

summary

B

grade

GLP-1 receptor agonists may reduce vascular complications in type 2 diabetes patients with diabetic retinopathy, but further prospective studies are needed to confirm these findings.

HR 0.65 for myocardial infarctions, 95% CI 0.61-0.69

summary

A

grade

iGlarLixi may provide better glycemic control and safety than IDegAsp in Chinese adults with type 2 diabetes, but findings should be interpreted with caution due to study limitations.

HbA1c reduction greater with iGlarLixi vs IDegAsp before lunch (-0.24%) or dinner (-0.29%).

summary

B

grade

Semaglutide shows a strong safety signal for optic ischaemic neuropathy, while lixisenatide does not present any safety concerns in this regard.

ROR 94.45 for semaglutide.

summary

B

grade

In 2024, only 5.5% of patients with type 1 diabetes used GLP-1 receptor agonists, and 0.9% used SGLT2 inhibitors, despite many having poor cardiometabolic control.

5.5% (3220/58,564) of patients used GLP-1 receptor agonists in 2024.

summary